Global Autoimmune Disease Testing Market to Reach USD 8.13 Billion by 2035 With CAGR 5.1%
Autoimmune Disease Testing Market
DE, UNITED STATES, February 25, 2026 /EINPresswire.com/ --
The global autoimmune disease testing market is witnessing steady expansion as healthcare systems intensify focus on early diagnosis and chronic disease management. Valued at USD 4.94 billion in 2025, the market is projected to reach USD 8.13 billion by 2035, growing at a CAGR of 5.1%. This growth is fueled by the rising global prevalence of autoimmune disorders, advancements in biomarker discovery, and the rapid adoption of automation and AI-integrated diagnostic platforms.
According to industry analysis, increasing cases of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, celiac disease, and other chronic autoimmune conditions are driving testing volumes worldwide. Early and accurate diagnosis has become critical, as autoimmune diseases often present overlapping symptoms that complicate clinical evaluation.
The Diagnostic Evolution: From Conventional Testing to Multiplex Precision
The autoimmune testing landscape is shifting from single-analyte assays toward multiplex, high-sensitivity platforms capable of detecting multiple biomarkers from a single sample. Laboratories are increasingly investing in automated immunoassay systems, chemiluminescence analyzers, and molecular diagnostic tools to enhance specificity and reduce turnaround time.
Reagents & consumables dominate the market with a 43.3% share in 2025, supported by high test volumes and the need for consistent diagnostic accuracy. Rheumatoid arthritis remains the leading indication, accounting for 31.9% of market revenue, as early detection through RF and anti-CCP antibody testing becomes standard clinical practice.
“We are seeing sustained demand for automation-friendly, multiplex solutions as laboratories manage growing caseloads,” noted a senior diagnostics executive during a recent industry briefing. “Precision and throughput are now non-negotiable.”
Point-of-Care and AI Integration Reshaping Access
Point-of-care (POC) and at-home testing solutions are gaining momentum, particularly in emerging markets and remote healthcare settings. Microfluidics and lab-on-a-chip technologies are enabling portable, cost-effective testing solutions that deliver rapid results without extensive laboratory infrastructure.
AI-driven diagnostic platforms and digital health integrations are further strengthening disease monitoring and personalized treatment strategies, aligning with the global shift toward precision medicine.
Regional Growth Outlook: Asia Pacific Emerging as Key Driver
While North America leads in market share due to strong healthcare infrastructure and established screening programs, Asia Pacific is projected to witness the fastest growth:
• India (6.2% CAGR): Expansion supported by rising healthcare access and increasing autoimmune awareness.
• China (5.8% CAGR): Growth driven by healthcare reforms and initiatives such as Healthy China 2030 promoting advanced diagnostics.
• United States (3.7% CAGR): Demand sustained by rising autoimmune prevalence and investment in AI-based diagnostics.
• Germany (3.4% CAGR): Government-backed research initiatives supporting biomarker innovation.
Market Metric | Value / Detail (2025–2035)
• Current Market Value (2025): USD 4.94 Billion
• Projected Market Value (2035): USD 8.13 Billion
• Global Growth Rate (CAGR): 5.1%
• Top Growth Market: India (6.2% CAGR)
• Leading Segment: Reagents & Consumables (43.3% Share)
Dynamics of the Decade: Precision, Accessibility, and Automation
• Biomarker Expansion: Advances in genomics and proteomics are enabling earlier detection and disease stratification.
• Decentralized Testing: Adoption of POC and home-based diagnostics is expanding access.
• Automation & AI: Smart analyzers and integrated data platforms are improving test reliability and reducing variability.
Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16969
Competitive Landscape
The market remains moderately consolidated, with Tier 1 companies accounting for 46.8% of global share. Key players include:
• Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Abbott
• Becton, Dickinson and Company
• PerkinElmer Inc.
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
Companies are focusing on biomarker-driven innovation, geographic expansion, and AI-enabled diagnostic platforms to strengthen competitive positioning.
Related Reports:
Autoimmune Disease Therapeutics Market:https://www.futuremarketinsights.com/reports/autoimmune-disease-therapeutics-market
Addison Disease Testing Market:https://www.futuremarketinsights.com/reports/addison-disease-testing-market
Legionnaire Disease Testing Market:https://www.futuremarketinsights.com/reports/legionnaire-disease-testing-market
Kinase Inhibitor in Autoimmune Diseases Market:https://www.futuremarketinsights.com/reports/kinase-inhibitor-in-autoimmune-diseases-market
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Delaware, USA, with a global delivery center in India and offices in the UK and UAE, FMI delivers actionable insights to businesses across industries including automotive, technology, consumer products, manufacturing, energy, and chemicals.
An ESOMAR-certified research organization, FMI provides custom and syndicated market reports and consulting services, supporting both Fortune 1,000 companies and SMEs. Its team of 300+ experienced analysts ensures credible, data-driven insights to help clients navigate global markets and identify growth opportunities.
For Press & Corporate Inquiries
Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
For web - https://www.futuremarketinsights.com/
Sudip Saha
Future Market Insights Inc.
+1 347-918-3531
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
